$PTN News

Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript

Transcript: Palatin Techs Q3 2026 Earnings Conference Call

Palatin Techs Q3 EPS $(0.37) Beats $(1.26) Estimate, Sales $3.921M Beat $1.283M Estimate

Palatin Technologies, Inc. Q2 2026 Earnings Call Summary

Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Techs Q2 EPS $(2.86) Misses $(2.69) Estimate, Sales $116.036K Beat $50.000K Estimate

Laidlaw & Co. Initiates Coverage On Palatin Techs with Buy Rating, Announces Price Target of $60

Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Palatin Techs Q1 EPS $4.26 Up From $(0.39) YoY, Sales $8.875M

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Boehringer Ingelheim marks retinal disease push with $327m licensing deal

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Palatin Announces 1-for-50 Reverse Stock Split

Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study